SCHEMBL2565337

SCHEMBL2565337

CC1(C)OCC(CN(c2ccccc2)S(=O)(=O)c2ccc(Cl)nc2)O1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
LMNA P02545 2/20 0.48
L3MBTL1 Q9Y468 4/20 0.45
POLB P06746 2/20 0.45
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
USP2 O75604 2/20 0.44
HPGD P15428 1/20 0.44
ALOX12 P18054 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
GPR55 Q9Y2T6 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
MAPT P10636 1/20 0.42
TMEM97 Q5BJF2 1/20 0.39
SIGMAR1 Q99720 1/20 0.39
PTPN22 Q9Y2R2 1/20 0.38
GAA P10253 1/20 0.36
HIF1A Q16665 2/20 0.36
EPAS1 Q99814 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2571249 0.86 MEN1 (0.49) ALDH1A1SMN1; SMN2LMNAL3MBTL1POLB
SCHEMBL2572673 0.80 MAPT (0.42) ALDH1A1SMN1; SMN2L3MBTL1POLBMEN1
SCHEMBL2565395 0.69 ALDH1A1 (0.70) ALDH1A1SMN1; SMN2LMNAL3MBTL1MEN1
SCHEMBL24416473 0.69 LMNA (0.43) ALDH1A1SMN1; SMN2LMNAMEN1KMT2A
SCHEMBL2569357 0.67 ALDH1A1 (0.65) ALDH1A1SMN1; SMN2LMNAL3MBTL1POLB
SCHEMBL8613559 0.67 KMT2A (0.86) ALDH1A1SMN1; SMN2LMNAL3MBTL1POLB
SCHEMBL3461457 0.66 FPR2 (0.44) ALDH1A1LMNAL3MBTL1POLBMEN1
SCHEMBL2571291 0.66 KDM4E (0.46) SMN1; SMN2LMNAPOLBMEN1KMT2A
SCHEMBL11895230 0.66 LMNA (0.36) ALDH1A1SMN1; SMN2LMNAL3MBTL1POLB
SCHEMBL10433871 0.65 CA2 (0.41) ALDH1A1SMN1; SMN2LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2382205-B1 DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS SANOFI SA (FR) 2014-04-23 EP disclosed
US-8541455-B2 Derivatives of 2-pyridin-2-yl-pyrazol-3(2H)-one, preparation and therapeutic use thereof as HIF activators SANOFI (FR) 2013-09-24 US disclosed
CN-102333769-A Derivatives of 2-pyridin-2-yl-pyrazol-3 (2H) -one, preparation thereof, and therapeutic use as HIF activators SANOFI AVENTIS 2012-01-25 CN disclosed
US-20110294788-A1 DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS SANOFI (FR) 2011-12-01 US disclosed
EP-2382205-A2 DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS SANOFI (FR) 2011-11-02 EP disclosed
WO-2010076524-A2 DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS SANOFI-AVENTIS (FR) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110294788-A1 DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS HIF1AN, HIF1A, EGLN2 ALDH1A1 1475/4885SMN1; SMN2 4107/4885LMNA 1891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.